Giuseppe
Emeritus
Vaccine. 2009 Mar 18;27(13):1889-97. Epub 2009 Feb 2.
A phase I clinical trial of a PER.C6((R)) cell grown influenza H7 virus vaccine.
Cox RJ, Madhun AS, Hauge S, Sjursen H, Major D, Kuhne M, H?schler K, Saville M, Vogel FR, Barclay W, Donatelli I, Zambon M, Wood J, Haaheim LR. Influenza Centre, - The Gade Institute, University of Bergen, N-5021 Bergen, Norway.
Avian influenza H7 viruses have transmitted from poultry to man causing human illness and fatality, highlighting the need for pandemic preparedness against this subtype. We have developed and tested the first cell-based human vaccine against H7 avian influenza virus in a phase I clinical trial.
Sixty healthy volunteers were intramuscularly vaccinated with two doses of split H7N1 virus vaccine containing 12mcg or 24mcg haemagglutinin alone or with aluminium hydroxide adjuvant (300mcg or 600mcg, respectively).
The vaccine was well tolerated in all subjects and no serious adverse events occurred. The vaccine elicited low haemagglutination inhibition and microneutralisation titres, although the addition of aluminium adjuvant augmented the antibody response.
We found a higher number of antibody secreting cells and an association with IL-2 production in subjects with antibody response. In conclusion, our study shows that producing effective H7 pandemic vaccines is as challenging as has been observed for H5 vaccines.
PMID: 19368768 [PubMed - in process]
-
------
A phase I clinical trial of a PER.C6((R)) cell grown influenza H7 virus vaccine.
Cox RJ, Madhun AS, Hauge S, Sjursen H, Major D, Kuhne M, H?schler K, Saville M, Vogel FR, Barclay W, Donatelli I, Zambon M, Wood J, Haaheim LR. Influenza Centre, - The Gade Institute, University of Bergen, N-5021 Bergen, Norway.
Avian influenza H7 viruses have transmitted from poultry to man causing human illness and fatality, highlighting the need for pandemic preparedness against this subtype. We have developed and tested the first cell-based human vaccine against H7 avian influenza virus in a phase I clinical trial.
Sixty healthy volunteers were intramuscularly vaccinated with two doses of split H7N1 virus vaccine containing 12mcg or 24mcg haemagglutinin alone or with aluminium hydroxide adjuvant (300mcg or 600mcg, respectively).
The vaccine was well tolerated in all subjects and no serious adverse events occurred. The vaccine elicited low haemagglutination inhibition and microneutralisation titres, although the addition of aluminium adjuvant augmented the antibody response.
We found a higher number of antibody secreting cells and an association with IL-2 production in subjects with antibody response. In conclusion, our study shows that producing effective H7 pandemic vaccines is as challenging as has been observed for H5 vaccines.
PMID: 19368768 [PubMed - in process]
-
------